We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+8.48%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$14.8B
AUM Growth
+$629M
(+4.4%)
Cap. Flow
-$312M
Cap. Flow
% of AUM
-2.1%
Top 10 Holdings %
Top 10 Hldgs %
24.14%
Holding
917
New
50
Increased
256
Reduced
457
Closed
57
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Veru
VERU
|
+$53M |
| 2 |
Mercado Libre
MELI
|
+$43.2M |
| 3 |
Darling Ingredients
DAR
|
+$41.7M |
| 4 |
Johnson & Johnson
JNJ
|
+$33.7M |
| 5 |
MetLife
MET
|
+$31.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PepsiCo
PEP
|
+$46.1M |
| 2 |
Nike
NKE
|
+$36.6M |
| 3 |
Illinois Tool Works
ITW
|
+$35.8M |
| 4 |
Apple
AAPL
|
+$31.9M |
| 5 |
Gilead Sciences
GILD
|
+$29.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 33.32% |
| 2 | Technology | 22.84% |
| 3 | Financials | 10.04% |
| 4 | Consumer Discretionary | 7.69% |
| 5 | Industrials | 7.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
T-Mobile US
TMUS
$190B
| $14.9M | 0.1% |
106,556
-8,698
| -8% | -$1.25M |
|
202
BioAtla
BCAB
$5.64M
| $14.9M | 0.1% |
36,108
-2,100
| -5% | -$871K |
|
203
Quest Diagnostics
DGX
$25.6B
| $14.9M | 0.1% |
95,071
+5,489
| +6% | +$789K |
|
204
Becton Dickinson
BDX
$43.8B
| $14.8M | 0.1% |
58,245
-15,089
| -21% | -$3.56M |
|
|
IPG
205
DELISTED
Interpublic Group of Companies
IPG
| $14.7M | 0.1% |
441,883
-209,905
| -32% | -$6.51M |
|
206
Hannon Armstrong Sustainable Infrastructure Capital
HASI
$4.91B
| $14.6M | 0.1% |
503,804
+94,518
| +23% | +$2.75M |
|
207
Mid-America Apartment Communities
MAA
$15.5B
| $14.6M | 0.1% |
92,904
+421
| +0.5% | +$65.6K |
|
208
Arrowhead Research
ARWR
$12B
| $14.5M | 0.1% |
358,054
-90,000
| -20% | -$2.98M |
|
|
ITOS
209
DELISTED
iTeos Therapeutics
ITOS
| $14.4M | 0.1% |
739,517
| – | – |
|
|
APLS
210
DELISTED
Apellis Pharmaceuticals
APLS
| $14.4M | 0.1% |
278,507
-65,000
| -19% | -$3.45M |
|
211
Veracyte
VCYT
$4.44B
| $14.3M | 0.1% |
602,146
+223,483
| +59% | +$5.19M |
|
212
Equity Residential
EQR
$25.2B
| $13.9M | 0.09% |
235,581
+155,816
| +195% | +$9.75M |
|
213
LPL Financial
LPLA
$26.5B
| $13.8M | 0.09% |
64,043
+43,760
| +216% | +$10.2M |
|
214
American Tower
AMT
$77.7B
| $13.6M | 0.09% |
64,360
-6,997
| -10% | -$1.46M |
|
215
Zoetis
ZTS
$32.2B
| $13.6M | 0.09% |
92,926
+9,315
| +11% | +$1.38M |
|
216
Arthur J. Gallagher & Co
AJG
$65.1B
| $13.5M | 0.09% |
71,855
-38,392
| -35% | -$7.18M |
|
|
IMGN
217
DELISTED
Immunogen Inc
IMGN
| $13.3M | 0.09% |
2,689,296
-165,339
| -6% | -$896K |
|
|
SCHW
218
Charles Schwab
SCHW
$181B
| $13.2M | 0.09% |
159,087
-32,021
| -17% | -$2.49M |
|
219
Axsome Therapeutics
AXSM
$12.3B
| $13.2M | 0.09% |
171,474
+61,094
| +55% | +$3.65M |
|
|
ACLX
220
DELISTED
Arcellx
ACLX
| $13.1M | 0.09% |
422,154
+388,931
| +1,171% | +$8.92M |
|
221
Sun Life Financial
SLF
$46B
| $12.9M | 0.09% |
278,757
-54,908
| -16% | -$2.43M |
|
222
Comcast
CMCSA
$80.9B
| $12.9M | 0.09% |
369,162
-308,415
| -46% | -$10.2M |
|
223
Wabtec
WAB
$50.8B
| $12.9M | 0.09% |
129,135
-1,639
| -1% | -$157K |
|
224
Kymera Therapeutics
KYMR
$9.05B
| $12.8M | 0.09% |
511,476
-38,142
| -7% | -$1.02M |
|
225
C.H. Robinson
CHRW
$20.6B
| $12.7M | 0.09% |
138,422
+98,467
| +246% | +$9.38M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q4 2022 Portfolio in Review
As of Q4 2022, Candriam SCA held 917 positions worth $14.8B, up 4.4% from $14.2B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Candriam SCA's Q4 2022 filing shows 50 new, 256 increased, 457 reduced and 57 closed positions. Its largest new stake was Sarepta Therapeutics: 95,144 shares worth $12.3M. The largest sale was PepsiCo, an estimated $46.1M.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 32% a quarter earlier, followed by Technology and Financials.
- Candriam SCA's largest Q4 2022 buy was Sarepta Therapeutics: 95,144 shares worth $12.3M.
- Candriam SCA added most to Veru in Q4 2022, an estimated $53M increase.
- Candriam SCA's biggest Q4 2022 reduction was PepsiCo, cutting an estimated $46.1M.
- Candriam SCA fully exited Global Blood Therapeutics, Inc. in Q4 2022, selling an estimated $24.6M.
- Candriam SCA's ten largest holdings make up 24% of its $14.8B portfolio in Q4 2022.
- Candriam SCA opened 50 new positions and closed 57 in Q4 2022.
- Candriam SCA's portfolio value rose 4.4% quarter-over-quarter to $14.8B.
Based on Candriam SCA's 13F filing for Q4 2022, filed 13 Feb 2023.